Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies

BACKGROUND AND OBJECTIVE: Proprotein convertase subtilisin/kexin type 9 inhibition with monoclonal antibodies such as alirocumab significantly reduces low-density lipoprotein-cholesterol levels ± other lipid-lowering therapies. We aimed to develop and qualify a population pharmacokinetics (PopPK) mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Djebli, Nassim, Martinez, Jean-Marie, Lohan, Laura, Khier, Sonia, Brunet, Aurélie, Hurbin, Fabrice, Fabre, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591810/
https://www.ncbi.nlm.nih.gov/pubmed/28063030
http://dx.doi.org/10.1007/s40262-016-0505-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591810/
https://www.ncbi.nlm.nih.gov/pubmed/28063030
http://dx.doi.org/10.1007/s40262-016-0505-1

Ejemplares similares